Clinical and Surrogate Endpoint Development for Regulatory Approval

This contract involves conducting research aimed at defining and validating clinical or surrogate endpoints to support regulatory submissions, with a particular focus on facilitating accelerated approval pathways. The work is designed to provide critical data that aids in meeting regulatory requirements, helping to streamline the approval process for new therapies or medical products. The subcontract, issued by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services, falls under the NAICS code 541715, which typically includes research and development in the physical, engineering, and life sciences. The place of performance is located in Silver Spring, with the contract posted for potential subcontracting opportunities on January 13, 2026. The emphasis on endpoint development highlights the importance of scientific validation in advancing medical innovation through regulatory channels.